News - Takeda Pharmaceuticals

Filter

Current filters:

Takeda Pharmaceuticals

Popular Filters

50 to 74 of 193 results

Three of Takeda's diabetes therapies get positive opinion from EMA unit

29-07-2013

Japan's largest drugmaker Takeda (TSE: 4502) has received a positive opinion from the European Medicines…

DiabetesEuropeIncresyncPharmaceuticalRegulationTakeda PharmaceuticalsVipdometVipidia

Evolution of Japan's pharma wholesalers - by P Reed Maurer

03-07-2013

Half of the definition for evolution (noun; a gradual process in which something changes especially into…

Asia-PacificFinancialMitsubishi TanabePharmaceuticalProductionSankyoShionogiTakeda Pharmaceuticals

$10 million milestone for Sucampo, as Takeda starts US selling of Amitiza for OIC

27-06-2013

USA-based Sucampo Pharmaceuticals (Nasdaq: SCMP) says that it has received a $10 million milestone payment…

AmitizaFinancialGastro-intestinalsMarkets & MarketingNorth AmericaPharmaceuticalSucampoTakeda Pharmaceuticals

Takeda files BLA for vedolizumab for Crohn's and ulcerative colitis in USA

21-06-2013

The US subsidiary of Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) has submitted a Biologics…

Gastro-intestinalsNorth AmericaPharmaceuticalRegulationTakeda Pharmaceuticalsvedolizumab

Takeda debuts three new diabetes drugs, Nesina, Kazano and Oseni, in USA

20-06-2013

Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) says that its new diabetes products Nesina…

DiabetesKazanoMarkets & MarketingNesinaNorth AmericaOseniPharmaceuticalTakeda Pharmaceuticals

Regulatory briefs: Sanofi's Fluzone; Roche' RoActemra; Takeda's Rienso

10-06-2013

French pharma major Sanofi (Euronext: SAN) today (June 10) announced that the US Food and Drug Administration…

Anti-Arthritics/RheumaticsBiotechnologyPharmaceuticalRegulationRocheSanofiTakeda PharmaceuticalsVaccines

Is the diabetes market facing a blockbuster-free future?

23-05-2013

Japanese drug major Takeda's (TYO: 4502) recently announced positive late-stage results for new type…

DiabetesfasiglifamMarkets & MarketingPharmaceuticalResearchTakeda Pharmaceuticals

Lundbeck and Takeda's Brintellix shows positive results in Ph III major depression study

20-05-2013

Danish CNS specialist Lundbeck (LUND: DC) and partner Takeda Pharmaceutical (TYO: 4502), Japan's largest…

BrintellixLundbeckNeurologicalPharmaceuticalResearchTakeda Pharmaceuticalsvortioxetine

Top-line financial results from Japanese drug majors

09-05-2013

Among a batch of Japanese drug majors presenting fiscal year 2013 (ended April 2013) financial results,…

Dainippon Sumitomo PharmaFinancialMitsubishi TanabePharmaceuticalShionogiTakeda Pharmaceuticals

Takeda to acquire Inviragen, gaining rights to promising vaccines

09-05-2013

Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) has entered into a definitive agreement to…

DENVaxInviragenMergers & AcquisitionsPharmaceuticalTakeda PharmaceuticalsVaccines

US Judge throws out verdict in Takeda Actos case

03-05-2013

The US subsidiary of Japan's largest drugmaker Takeda Pharmaceuticals (TYO: 4502) USA announced that,…

ActosDiabetesLegalNorth AmericaPharmaceuticalTakeda Pharmaceuticals

Vedolizumab has potential to offer improvement over infliximab in UC

30-04-2013

Surveyed US and EU5 gastroenterologists agree that new moderate to severe ulcerative colitis (UC) therapies…

EuropeGastro-intestinalsinfliximabJanssenMarkets & MarketingMerck & CoNorth AmericaPharmaceuticalRemicadeTakeda Pharmaceuticalsvedolizumab

Oxford BioThera and Boehringer Ingelheim collaborate; Milestone for Heptares

29-04-2013

The UK's Oxford BioTherapeutics (OBT) and family-owned German drug major Boehringer Ingelheim have entered…

Boehringer IngelheimHeptares TherapeuticsLicensingNeurologicalOncologyOxford BioTherapeuticsPharmaceuticalResearchTakeda Pharmaceuticals

Takeda considering options over US Actos court ruling

29-04-2013

The US subsidiary of Japan's largest drugmaker, Takeda Pharmaceuticals (TYO 4502), says that in the case…

ActosDiabetesLegalNorth AmericaPharmaceuticalTakeda Pharmaceuticals

MHLW joins Japan's first P-PP to facilitate R&D of new health technologies for the developing world

08-04-2013

The Japanese Ministry of Health, Labor and Welfare (MHLW) has said it supports the research and development…

Asia-PacificAstellas PharmaDaiichi SankyoEisaiFinancialHealthcarePharmaceuticalResearchShionogiTakeda PharmaceuticalsTropical diseases

Strong results from meta-analysis of Takeda's Velcade in multiple myeloma

08-04-2013

Millennium, the USA-based oncology unit of Japan's largest drugmaker Takeda Pharmaceutical (TSE:4502),…

Millennium PharmaceuticalsOncologyPharmaceuticalResearchTakeda PharmaceuticalsVelcade

Takeda files for brentuximab vedotin approval in Japan; sanctioned by JPMA

22-03-2013

Japan's largest drugmaker, Takeda Pharmaceutical (TYO: 4502) and its oncology subsidiary Millennium have…

AdcetrisAlinamin-F5Asia-PacificbrentuximabMillennium LaboratoriesOncologyPharmaceuticalRegulationSeattle GeneticsTakeda Pharmaceuticals

Takeda expands Latin America footprint with new subsidiary in Ecuador

21-03-2013

Japan's largest drugmaker Takeda Pharmaceuticals (TYO: 4502) says it is expanding its presence in Latin…

ManagementMarkets & MarketingPharmaceuticalSouth AmericaTakeda Pharmaceuticals

NPS Pharma regains rights to Revestive and Preotact from Takeda

20-03-2013

USA-based NPS Pharmaceuticals (Nasdaq: NPSP) has re-gained the full worldwide rights from partner Takeda…

Anti-Arthritics/RheumaticsGastro-intestinalsGattexLicensingNatparaNPS PharmaceuticalsPharmaceuticalPreotactRevestiveTakeda Pharmaceuticals

Eisai slams German decision on Fycompa; Takeda files vedolizumab with EMA

08-03-2013

The German Federal Joint Committee (G-BA), the decision-making body of the self-governing medical system…

EisaiEuropeFycompaGastro-intestinalsNeurologicalPharmaceuticalRegulationTakeda Pharmaceuticalsvedolizumab

50 to 74 of 193 results

Back to top